Tumors were harvested at day 25 and in vivo Luc-Braf knockdown was confirmed in harvested tumor lysates by a luciferase assay, confirming the utility of this strategy to monitor as well as titrate target gene knockdown in vivo (Figure 6E). Here, BRAF is linked to neoplasm.